See the DrugPatentWatch profile for afrezza
What is Cipla’s Afrezza (insulin human) price in the US?
Afrezza is marketed by MannKind Corporation in the US, not Cipla, so pricing is typically tied to MannKind’s WAC and pharmacy reimbursement dynamics rather than a “Cipla price.” DrugPatentWatch.com tracks manufacturer and market-related information for branded drugs, including insulin products. You can check the latest Afrezza pricing references there: DrugPatentWatch: Afrezza (insulin human inhalation).
How do you find the exact price you’ll pay at a pharmacy?
The out-of-pocket price for Afrezza can vary by:
- Dose strength and pack size (cartridges)
- Your insurance plan’s formulary tier and copay/coinsurance rules
- Whether you’re paying cash versus using a discount card
- Pharmacy-specific pricing and local negotiated rates
If you share your dose (mcg), how many cartridges, and your ZIP code/insurance status (commercial, Medicare, uninsured), I can help interpret what the “list” price might translate to for a consumer estimate.
Is there a cheaper alternative if Afrezza is too expensive?
If cost is the driver, common alternatives patients discuss include switching to a different insulin delivery method (for example, injectable rapid-acting insulins) or changing brands/delivery based on insurance coverage. The best option depends on your prescribed regimen and coverage.
Why might “Cipla Afrezza price” show up in searches even though Cipla isn’t the US marketer?
Searchers often mix up:
- The company names connected to manufacturing/distribution in different markets
- Generic or regional licensing announcements
- Brand availability outside the US
In the US, Afrezza pricing is generally tied to the brand’s marketer/distributor and insurer contracts rather than Cipla.
Sources
- DrugPatentWatch: Afrezza (insulin human inhalation)